Research Applications
Obesity and Metabolic Syndrome
In the primary preclinical study (Billon et al., 2024), administration of SLU-PP-332 to obese mice (50 mg/kg IP, twice daily, 28 days) resulted in 10-fold less fat mass accumulation compared to controls and 12% body weight reduction. The compound reduced hepatic steatosis and improved glucose tolerance in metabolic syndrome models.
Exercise Endurance Enhancement
SLU-PP-332 is classified as an "exercise mimetic." Mice receiving the compound ran 70% longer and covered 45% greater distances compared to controls. Increased type IIa oxidative muscle fibers confirm direct muscle adaptation to endurance exercise.
Type 2 Diabetes
Improved insulin sensitivity and enhanced glucose utilization through increased GLUT4 expression make SLU-PP-332 a potential candidate for insulin resistance therapy. However, clinical data are lacking.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Significant reduction in hepatic steatosis in mice indicates potential for NAFLD/NASH treatment. The mechanism involves enhanced hepatocyte fatty acid oxidation and reduced de novo lipogenesis.
Sarcopenia and Age-Related Muscle Atrophy
Recent research (Frontiers in Physiology, 2025) explores ERR agonists for combating age-related muscle loss. ERR activation may counteract the decline in mitochondrial function characteristic of aging skeletal muscle.
Mechanism of Action
ERR Receptor Activation
SLU-PP-332 binds to nuclear receptors of the ERR family (Estrogen-Related Receptors) — ERRα, ERRβ, and ERRγ, acting as a pan-agonist with preferential activity at ERRα. These receptors are not directly involved in estrogen signaling but are key regulators of energy metabolism. ERRα is highly expressed in energy-demanding tissues — skeletal muscle, heart, and brown adipose tissue.
Activation of Aerobic Exercise Transcriptional Program
Upon binding to ERRα, SLU-PP-332 triggers expression of hundreds of exercise-associated genes. Key targets include PGC-1α (master regulator of mitochondrial biogenesis) and GLUT4 (glucose transporter upregulated by insulin and exercise). This shifts skeletal muscle toward oxidative metabolism without the mechanical stress of actual training.
Mitochondrial Function Enhancement
SLU-PP-332 significantly enhances mitochondrial respiration and fatty acid oxidation in skeletal muscle cells (C2C12 myocytes). The compound increases the proportion of type IIa oxidative fibers in skeletal muscle — a hallmark effect of aerobic training.
Increased Energy Expenditure
The compound increases resting energy expenditure by accelerating fat metabolism. This effect occurs without affecting appetite, food intake, or locomotor activity — the drug makes the body function as if it is exercising, resulting in enhanced fat burning.
Biological Pathways
ERRα/PGC-1α Signaling Cascade
The primary pathway involves ERRα activation, which is co-activated by PGC-1α. This tandem drives transcription of oxidative phosphorylation, mitochondrial biogenesis, and fatty acid β-oxidation genes. ERRα phosphorylates and activates promoters of electron transport chain genes (NDUFV1, SDHA, UQCRC1, COX5A) and citrate synthase.
Mitochondrial Biogenesis
Through the PGC-1α → NRF-1/NRF-2 → TFAM cascade, SLU-PP-332 stimulates mitochondrial DNA replication and assembly of new mitochondria, increasing overall muscle oxidative capacity and shifting metabolism from glycolytic to oxidative type.
AMPK/SIRT1 Pathway
ERR-dependent metabolic activation increases the AMP/ATP ratio, activating AMPK — a key cellular energy status sensor. AMPK stimulates catabolic processes (fatty acid oxidation, autophagy) and inhibits anabolic ones (lipogenesis, protein synthesis via mTORC1 suppression).
Muscle Fiber Type Remodeling
SLU-PP-332 shifts muscle fiber composition toward oxidative type IIa through calcineurin/NFAT and MEF2-dependent transcription activation. This is physiologically equivalent to adaptation to aerobic endurance training.
Dosage Information
Reconstitution Notes
Dissolve in DMSO (58 mg/mL). For in vivo studies — dilute in an appropriate vehicle. Insoluble in water. For preclinical research only — human dosages have not been established.
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
SLU-PP-332 — Metabolic EnhancementAdvanced⚖️Weight Loss28 days (protocol per Billon et al., 2024)
Experimental protocol based on the exercise mimetic SLU-PP-332 (ERRα/β/γ agonist) for enhancing fat oxidation, increasing endurance, and improving metabolic profile. For preclinical research only.
Warning: FOR RESEARCH PURPOSES ONLY. Not approved for human use. All data from mouse experiments. Human dosages not established. Long-term safety not studied. WADA may classify as a prohibited substance (category S4). Not recommended for athletes.
Stability & Storage
SLU-PP-332 in powder form is stable at -20°C for 3 years in sealed packaging protected from light and moisture. Stock solutions in DMSO are stable at -80°C for up to 1 year and at -20°C for up to 1 month.
Solubility: freely soluble in DMSO (58 mg/mL, 199.77 mM), limited in ethanol (2 mg/mL), insoluble in water. For research purposes, preparation of stock solutions in DMSO with subsequent dilution in an appropriate vehicle is recommended.
In preclinical studies, the compound was administered intraperitoneally in oil or DMSO-containing vehicle. Oral bioavailability and pharmacokinetics for oral formulations are under investigation — authors note the need for structural optimization to develop a tablet formulation.
Plasma and muscle exposure is 0.2 μM and 0.6 μM respectively, 6 hours after intraperitoneal injection (30 mg/kg).
Side Effects & Precautions
Preclinical Observations (Mice)
In the primary study (Billon et al., 2024), only minor changes in plasma cholesterol levels and liver enzymes were noted. No significant liver, kidney, or cardiovascular toxicity was identified within the 28-day protocol.
Tolerability Issues in ob/ob Mice
In genetically obese ob/ob mice, treatment duration was shortened to 12 days due to tolerability issues. Specific manifestations of intolerance were not detailed in the publication, but this may indicate more pronounced side effects in severe obesity.
Mechanism of Action and Safety
SLU-PP-332 works through gene transcription and nuclear receptor activation, not through hormonal axes. It does not suppress endogenous hormones, stimulate appetite, or act as a CNS stimulant. The mechanism does not involve the hypothalamic-pituitary axis, theoretically reducing the risk of endocrine side effects.
Unknown Risks
All safety data come from short-term mouse studies. No data exist regarding: long-term toxicity, carcinogenicity, teratogenicity, drug interactions, or human safety. Until comprehensive toxicological studies and Phase I clinical trials are conducted, the safety profile of SLU-PP-332 remains uncertain.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
SLU-PP-332 is an experimental research compound (research chemical). It is not approved by the FDA, EMA, or any other regulatory agency for human medical use. All available data are derived exclusively from preclinical mouse studies.
The compound is at the preclinical optimization stage. Next development steps include: structural modification for improved pharmacokinetics (oral formulation development), expanded toxicological studies in multiple animal species, and preparation for Phase I clinical trials.
WADA (World Anti-Doping Agency) may classify SLU-PP-332 as a prohibited substance under category S4 (hormone and metabolic modulators) due to its exercise-mimetic properties. Athletes should avoid using this compound.
Commercially available research-grade SLU-PP-332 has purity ≥98-99.5% (HPLC) and is available through reagent suppliers (Sigma-Aldrich, Selleck, Tocris, Cayman Chemical) exclusively for laboratory research.
Research Studies
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP.
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Burris TP.
Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study
Various
SLU-PP-332 and Related ERRα Agonists: A Focused Minireview of Metabolic Regulation and Therapeutic Potential
Various
Related Peptides
Semaglutide
Ozempic, Wegovy +3 more
Tesamorelin
Tesamorelin Acetate, Egrifta +2 more
Tirzepatide
Mounjaro, Zepbound +2 more
AOD-9604
Advanced Obesity Drug 9604, hGH Fragment 176-191 +3 more
Retatrutide
LY3437943, Reta +1 more
Dulaglutide
Trulicity, LY2189265